Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9405138 | 0.90 | FTO (0.54) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL15902813 | 0.88 | FTO (0.55) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL6479542 | 0.87 | FTO (0.58) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL5497268 | 0.84 | FTO (0.48) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL8647706 | 0.84 | FTO (0.48) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL7621360 | 0.84 | FTO (0.48) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2105358 | 0.84 | FTO (0.48) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL139173 | 0.82 | FTO (0.65) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL1235458 | 0.81 | FTO (0.52) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL25220939 | 0.81 | HPGD (0.52) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010010920-A1 | Monoclonal antibodies obtained using rapamycin position 27 conjugates as an immunogen | WYETH | 2001-08-02 | — | — | US | claimed |
| EP-0710110-A4 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LAB (US) | 1997-06-18 | — | — | EP | claimed |
| EP-0710110-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LABORATORIES (US) | 1996-05-08 | — | — | EP | claimed |
| WO-1994025022-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LABORATORIES (US) | 1994-11-10 | — | — | WO | claimed |
| EP-1181938-B1 | Rapamycin conjugates and antibodies | WYETH CORP (US) | 2007-11-14 | — | — | EP | disclosed |
| US-6541612-B2 | Complex of rapamycin-42 ester with dicarboxylic acid and fluorescein; antibody detection/generation; immunoglobulins; hybridomas; ring opening; precipitation | WYETH | 2003-04-01 | — | — | US | disclosed |
| EP-0710110-B1 | ANTIBODIES OF RING OPENED RAPAMYCINS | ABBOTT LAB (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1181938-A2 | Rapamycin conjugates and antibodies | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6328970-B1 | Rapamycin position 27 conjugates | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-11 | — | — | US | disclosed |
| US-20010010920-A1 | Monoclonal antibodies obtained using rapamycin position 27 conjugates as an immunogen | WYETH | 2001-08-02 | — | — | US | disclosed |
| EP-0710110-A4 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LAB (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0710110-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LABORATORIES (US) | 1996-05-08 | — | — | EP | disclosed |
| US-5504091-A | IMMUNOSUPPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1994025022-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LABORATORIES (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994025072-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994025468-A1 | BIOTIN ESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010010920-A1 | Monoclonal antibodies obtained using rapamycin position 27 conjugates as an immunogen | RICTOR, MLST8, MAPKAP1 | FTO 3602/4885MAPT 2299/4885HPGD 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.